Trial progress: Social media discussions center on Viking Therapeutics advancing its obesity pipeline with the start of a Phase 1 single ascending dose study for VK3019. Preclinical data suggesting rapid weight loss in animal models has sparked interest among observers. The company also confirmed that results from the Phase 1 maintenance study of VK2735 are expected in the third quarter.
Market comparisons: Participants compare VKTX to peers in the obesity space, noting its potential for both injectable and oral formulations. Some highlight the appeal of trading options ahead of data readouts given known timelines. Overall, the tone reflects measured excitement around the broadening pipeline without overcommitting to specific outcomes.
Note: This discussion summary was generated from an AI condensation of post data.
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 14 times in the past 6 months. Of those trades, 1 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- BRIAN LIAN (President & CEO) has made 0 purchases and 4 sales selling 233,409 shares for an estimated $7,692,120.
- MARIANNA MANCINI (Chief Operating Officer) has made 0 purchases and 4 sales selling 57,661 shares for an estimated $1,901,405.
- GREG ZANTE (Chief Financial Officer) has made 0 purchases and 4 sales selling 57,661 shares for an estimated $1,896,969.
- MATTHEW W FOEHR sold 16,000 shares for an estimated $561,694
- NEIL WILLIAM AUBUCHON (Chief Commercial Officer) purchased 4,475 shares for an estimated $149,912
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Viking Therapeutics Hedge Fund Activity
We have seen 221 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 224 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 2,030,259 shares (-78.8%) from their portfolio in Q4 2025, for an estimated $71,424,511
- TWO SIGMA INVESTMENTS, LP added 1,996,405 shares (+82.0%) to their portfolio in Q1 2026, for an estimated $64,963,018
- AMERICAN CENTURY COMPANIES INC added 1,773,211 shares (+580.7%) to their portfolio in Q1 2026, for an estimated $57,700,285
- NORGES BANK removed 1,767,777 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $62,190,394
- D. E. SHAW & CO., INC. added 1,557,136 shares (+965.0%) to their portfolio in Q4 2025, for an estimated $54,780,044
- RAYMOND JAMES FINANCIAL INC added 1,153,405 shares (+125.1%) to their portfolio in Q1 2026, for an estimated $37,531,798
- VESTAL POINT CAPITAL, LP added 914,147 shares (+inf%) to their portfolio in Q1 2026, for an estimated $29,746,343
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Viking Therapeutics Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 4 analysts offer price targets for $VKTX in the last 6 months, with a median target of $101.0.
Here are some recent targets:
- Daniel Brims from Lake Street set a target price of $89.0 on 05/28/2026
- Jeet Mukherjee from BTIG set a target price of $125.0 on 05/01/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $100.0 on 04/30/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $102.0 on 03/23/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
